Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development. This segment also provides individual services, including product development and regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health, clinical trial diversity, biometric, and regulatory affair services. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication services; and consulting services to the pharmaceutical, biotechnology, and healthcare industries. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.

Syneos Health, Inc.

AHRM is a specialty CRO that focuses on Health Economics and Outcomes Research. The company integrates and conducts clinical trials and outcomes research across various therapeutic areas.

Applied Healthcare Research Management Inc. (AHRM)

Evolve Clinical Research is a multi-site network that increases the availability of clinical trials by embedding research sites within physicians' offices.

Evolve Clinical Research

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Idorsia Ltd

Syneos Health is a fully integrated biopharmaceutical solutions organization that focuses on accelerating customer success through unique clinical, medical affairs, and commercial insights. It is self-described as a partner that listens and brings specialized experts to improve performance and speed therapies to patients.

Metric
Company Name	Syneos Health, Inc.	Applied Healthcare Research Management Inc. (AHRM)	Evolve Clinical Research	Idorsia Ltd
Symbol	SYNH			IDIA
MSH ID	COM:SYNEOSHEALTH	COM:AHRMINC	COM:EVOLVECLINICALRESEARCH	COM:IDORSIA
Market	STOCKS	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services
Industry	Medical - Diagnostics & Research	Contract Research Organization (CRO)	Clinical Research
Country	US	US	US	CH
Stage				Post-IPO Debt
Employee Count	28.77K			636
Website	syneoshealth.com	ahrminc.com	evolveclinicalresearch.com	idorsia.com
LinkedIn		applied-healthcare-resource-management
Founders

Metric
Market Cap	4.46B		311.77M
Enterprise Value
Monthly Web Traffic		1	19.83K
Web Traffic Growth			1.09
Valuation
Raised Capital			83.54M

Metric
Revenue	5.39B	173.71M
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.25B	143.86M
EBITDA	699.99M	-597.34M
Operating Income	403.19M	-619.04M
Net Income	266.50M	-339.61M
EPS	2.57	-1.90
Diluted EPS	2.54	-1.90
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.22	0.95
Operating Profit Margin	0.05	-0.52
EBITDA Margin	0.13	-3.44
Net Profit Margin	0.01	0.31
Return on Equity	0.02	0.44
Return on Assets	0.01	0.06
Return on Capital Employed	0.05	-0.29

COM:SYNEOSHEALTH

Syneos Health

Last Close

42.97

27/09 20:00

Market Cap

4.46B

Beta: -

Volume Today

6.70M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	62.57	-0.73
P/B Ratio	1.28	-0.33
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	0.82	4.46
EV Multiple	3.00	14.37

Metric
Days Sales Outstanding	114.47	52.13
Days Payables Outstanding	11.85	751.10
Days Inventory Outstanding	0.01	2.47K
Operating Cycle	114.48	2.52K
Cash Conversion Cycle	102.63	1.77K
Asset Turnover	0.67	0.28

Metric
Operating Cash Flow		-717.35M
Free Cash Flow		-728.06M
Cash Flow to Debt	0.09	-0.35
Operating Cash Flow/Sales	0.05	-3.00
Free Cash Flow Yield	0.04	-2.60

Metric
Cash & Equivalents	112.00M	165.35M
Accounts Receivable		-14.68M
Inventory		67.42M
Goodwill	4.90B
Debt to Capitalization	0.45	11.32
Debt to Assets	0.36	1.85
Current Ratio	1.20	1.21
Quick Ratio	1.09	1.00

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.01	0.18
R&D to Revenue		1.94
SG&A to Revenue		4.00